315 iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model

• Haruhiko Koseki,
• Lilin Zhang,
• Yuji Mishima,
• Akane Urakami,
• Koichiro Shioya,
• Tomokuni Shigeura,
• Tomio Matsumura,
• Momoko Okoshi

Affiliations

Haruhiko Koseki

2RIKEN, Yokohama, Kanagawa, Japan

Lilin Zhang

1BrightPath Biotherapeutics Co., Ltd., Kawasaki, Kanagawa, Japan

Yuji Mishima

1BrightPath Biotherapeutics Co., Ltd., Kawasaki, Kanagawa, Japan

Akane Urakami

1BrightPath Biotherapeutics Co., Ltd., Kawasaki, Kanagawa, Japan

Koichiro Shioya

1BrightPath Biotherapeutics Co., Ltd., Kawasaki, Kanagawa, Japan

Tomokuni Shigeura

1BrightPath Biotherapeutics Co., Ltd., Kawasaki, Kanagawa, Japan

Tomio Matsumura

1BrightPath Biotherapeutics Co., Ltd., Kawasaki, Kanagawa, Japan

Momoko Okoshi

2RIKEN, Yokohama, Kanagawa, Japan